Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG6002 plus Flucytosine in Advanced GI Tumors
NCT03724071Phase 2Terminated
- Sponsor
- Transgene SA
- Start
- Oct 2018
- Primary completion
- Feb 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 3
01
Overview
Phase 2, open-label trial of TG6002 in gastrointestinal cancer, colorectal cancer (CRC) and liver metastases (3 arms), sponsored by Transgene SA. Primary endpoints: Dose-limiting toxicities at Day 28 and Overall Response Rate at Day 43. Started Oct 2018; status: terminated.
02
Drugs
TG6002
03
Conditions
gastrointestinal cancercolorectal cancer (CRC)liver metastases
Beyond the preview
Go deeper on NCT03724071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724071.